Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Paclitaxel,PTXStudy001,2022,USA,MDV,350,62,65,35,26.5,28,85,12,15,40,30,15,55,25,15,5,20,45,30,10,3,2,5,4,35,60,45,AC,Taxol/Carbo,TC,CMF,20,15,10,30,70,50,15,40,45,60,2
Paclitaxel,PTXStudy002,2023,Canada,Claim Database,420,68,68,32,27.1,31,82,15,18,38,28,16,52,28,14,6,22,43,29,12,4,3,6,5,38,63,48,EC,Docetaxel/Carbo,AC-T,FEC,22,17,12,33,73,53,18,43,39,63,3
Paclitaxel,PTXStudy003,2023,UK,MDV,280,70,70,30,28.5,35,78,18,20,35,25,20,50,30,12,8,25,40,25,15,5,4,7,6,40,65,50,FEC,Taxol/Herceptin,Docetaxel/Cyclophosphamide,EC,25,20,15,35,75,55,20,45,35,65,4
